Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 1, 2005, Pages 461-463

  Lomaestro, Ben M ^a   Drusano, G L ^b  

^a ALBANY MEDICAL CENTER   (United States)

^b ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CILASTATIN PLUS IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ACINETOBACTER; ARTICLE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG INFUSION; DRUG TARGETING; ENTEROBACTER; HOSPITAL INFECTION; HUMAN; HUMAN EXPERIMENT; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SERRATIA; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CILASTATIN; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PSEUDOMONAS AERUGINOSA; THIENAMYCINS; TIME FACTORS;

EID: 11244334599     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.1.461-463.2005     Document Type: Article

References (12)

1. Bauernfeind, A., and F. Sörgel. 1997. Comparative bactericidal effect of discontinuous vs. continuous dosing of meropenem in a pharmacodynamic model, abstr. A36. Abstr. 37th Intersci. Conf. Antimicrob. Agents Chemother., 28 September to 1 October, Toronto, Ontario, Canada.
2. Craig, W. A., S. Ebert, and Y. Watanabe. 1993. Differences in time above MIC (T>MIC) required for efficacy of beta-lactams in animal infection models, abstr. 86. Program Abstr. 33rd Intersci. Conf. Antimicrob. Agents Chemother., New Orleans, La.
3. D'Argenio, D. Z., and A. Schumitzky. ADAPT II user's guide. University of Southern California, Los Angeles.
4. Domenig, C., F. Traunmuller, S. Kozek, W. Wisser, W. Klepetko, et al. 2001. Continuous beta-lactam antibiotic therapy in a double-lung transplanted patient with a multidrug-resistant Pseudomonas aeruginosa infection. Transplantation 71:744-745.
5. Drusano, G. L., H. C. Standiford, C. Bustamante, A. Forrest, G. Rivera, J. Leslie, B. Tatem, D. Delaportas, R. R. MacGregor, and S. C. Schimpff. 1984. Multiple-dose pharmacokinetics of imipenem-cilastatin. Antimicrob. Agents Chemother. 26:715-721.
6. Drusano, G. L., and M. Hutchison. 1995. The pharmacokinetics of meropenem. Scand. J. Infect. Dis. Suppl. 96:11-16.
7. Drusano, G. L. 2003. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin. Infect. Dis. 36(Suppl. 1):S42-S50.
8. Firsov, A. A., and H. Mattie. 1997. Relationships between antimicrobial effect and area under the concentration-time curve as a basis for comparison of modes of antibiotic administration: meropenem bolus injections versus continuous infusions. Antimicrob. Agents Chemother. 41:352-356.
9. Keil, S., and B. Wiedemann. 1997. Antimicrobial effects of continuous versus intermittent administration of carbapenem antibiotics in an in vitro dynamic model. Antimicrob. Agents Chemother. 41:1215-1219.
10. Sörgel, F., K. G. Naber, A. Bauernfeind, M. Kinzig-Schippers, H. Schuhmacher, G. Rüsing, and A. Bergmann. 1997. Pharmacokinetics and pharmacodynamics of meropenem after intermittent and continuous infusion in healthy volunteers, abstr. A49. Abstr. 37th Intersci. Conf. Antimicrob. Agents Chemother., 28 September to 1 October, Toronto, Ontario, Canada.
11. Thalhammer, F., F. Traunmuller, I. El Menyawi, M. Frass, U. M. Hollenstein, et al. 1999. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J. Antimicrob. Chemother. 43:523-527.
12. Turnidge, J. D. 1998. The pharmacodynamics of beta-lactams. Clin. Infect. Dis. 27:10-22.